

Katelyn W Sylvester

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2016116/publications.pdf>

Version: 2024-02-01

45
papers

545
citations

759233

12
h-index

677142

22
g-index

45
all docs

45
docs citations

45
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin. <i>Thrombosis Research</i> , 2022, 218, 199-200.	1.7	3
2	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
3	Optimization of DOAC management services in a centralized anticoagulation clinic. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12696.	2.3	10
4	A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation. <i>Transplantation</i> , 2022, 106, 2143-2154.	1.0	1
5	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	2.1	3
6	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.	2.1	0
7	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12521.	2.3	3
8	Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12573.	2.3	3
9	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	1.7	8
10	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.5	1
11	VTE in ICU Patients With COVID-19. <i>Chest</i> , 2020, 158, 2130-2135.	0.8	76
12	Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2532-2541.	3.8	20
13	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.	2.1	0
14	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.5	1
15	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	1.5	0
16	Coordinating emergent procedures after andexanet alfa. <i>American Journal of Hematology</i> , 2019, 94, E278-E282.	4.1	9
17	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.	1.7	20
18	Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 136-137.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983736.	1.7	10
20	Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983348.	1.7	4
21	Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report. <i>A&A Practice</i> , 2019, 13, 271-273.	0.4	30
22	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71.	0.5	17
23	Andexanet alfa—The first 150 days. <i>American Journal of Hematology</i> , 2019, 94, E21-E24.	4.1	26
24	Cerebrovascular Accidents During Mechanical Circulatory Support. <i>Stroke</i> , 2018, 49, 1197-1203.	2.0	21
25	Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 274-280.	2.1	26
26	Description and Evaluation of the Implementation of a Weight-Based, Nurse-Driven Heparin Nomogram in a Tertiary Academic Medical Center. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 248-253.	1.7	15
27	Utilization of an Integrated Electronic Health Record in the Emergency Department to Increase Prospective Medication Order Review by Pharmacists. <i>Journal of Pharmacy Practice</i> , 2018, 31, 636-641.	1.0	3
28	Betrixaban in the prevention of venous thromboembolism in medically ill patients. <i>Future Cardiology</i> , 2018, 14, 455-470.	1.2	2
29	Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 178S-181S.	1.7	10
30	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 180-185.	2.1	16
31	Evaluation of Compliance with a Weight-based Nurse-driven Heparin Nomogram in a Tertiary Academic Medical Center. <i>Critical Pathways in Cardiology</i> , 2018, 17, 83-87.	0.5	5
32	Comparison of an IgG-Specific Enzyme-Linked Immunosorbent Assay Cutoff of 0.4 Versus 0.8 and 1.0 Optical Density Units for Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 282-286.	1.7	7
33	Development of a Predictive Nomogram for the Change in PT/INR Upon Discontinuation of Bivalirudin as a Bridge to Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 487-493.	1.7	5
34	Prospective evaluation of a bivalirudin to warfarin transition nomogram. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 498-504.	2.1	3
35	Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 405-409.	1.7	8
36	Warfarin management in the setting of FVII deficiency and mechanical circulatory support. <i>Vascular Medicine</i> , 2017, 22, 345-346.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report. American Journal of Hematology, 2017, 92, E34-E35.	4.1	15
38	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. Current Emergency and Hospital Medicine Reports, 2016, 4, 93-97.	1.5	3
39	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. American Journal of Medicine, 2016, 129, 1198-1204.	1.5	121
40	Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency. American Journal of Hematology, 2015, 90, E185.	4.1	1
41	Pharmacy Response to the Boston Marathon Bombings at a Tertiary Academic Medical Center. Annals of Pharmacotherapy, 2014, 48, 1082-1085.	1.9	2
42	Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2013, 33, 1191-1198.	2.6	7
43	Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners. Current Emergency and Hospital Medicine Reports, 2013, 1, 226-235.	1.5	8
44	Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vascular Health and Risk Management, 2013, 9, 245.	2.3	10
45	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. Blood, 2011, 118, 2062-2062.	1.4	4